Holliston

With the threat of NASDAQ delisting looming, executives at Holliston-based Biostage Inc. are looking for new ways to finance the continued development of its regenerative platform.

Holliston life sciences company Harvard Bioscience has elected James Green, the former president and CEO of Analogic Corp., as its new board chairman.

Biostage will be delisted from the NASDAQ stock market if it loses an upcoming appeal, after the company failed to raise its bid price to $1 within a given 180-day period.

Looking for a place where they could provide steady employment for adult children with developmental disabilities, the Giammarinaros three years ago took over ownership of a two-year dormant miniature golf course and created a four-acre family entertainment center.

Biostage, which develops bioengineered organ implants, reported it lost $3.8 million in the first quarter, leaving it with only enough cash through the end of the year.

Harvard Bioscience, a Hollison life science instrument company, lost more than $1 million in the first quarter as revenue fell from the prior year.

Cold Chain Technologies, which designs, tests and manufactures thermal packaging solutions for the life science industry, on Monday announced the opening of its new facility in Franklin.

Greater Boston Commercial Properties of Northborough announced this week that it helped lease two MetroWest properties.

A former manufacturing building in Holliston has sold for $1.15 million, according to Greater Boston Commercial Properties, Inc., which completed the deal.

Holliston organ implant company Biostage is offering roughly $8 million in stock, three months after it was threatened to be removed from the NASDAQ stock exchange.